Introduction {#s1}
============

Rett syndrome (RTT) is a severe progressive neurodevelopmental disorder, mainly caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2), a protein involved in transcriptional regulation ([@bib2]; [@bib63]; [@bib66]). RTT patients show regression of head growth followed by various neurological symptoms including seizures, mental retardation, stereotypic hand-wringing movements, breathing irregularities, ataxia and autistic behavior ([@bib54]). Mouse models with *Mecp2* mutations display similar neurological phenotypes, and have been quite critical in defining the pathophysiology of RTT. *Mecp2^Null/y^* mice grow normally until 4--6 weeks of age, after which they display RTT-like symptoms such as reduced mobility, hindlimb clasping, abnormal breathing patterns and premature death ([@bib15]; [@bib27]). Similarly, mice engineered to express twice the endogenous levels of MeCP2 (*Mecp2^Tg1^*) are characterized by seizures, forepaw clasping, hypoactivity, increased aggression, and around 30% die by one year of age ([@bib17]; [@bib31]; [@bib43]). Loss or doubling of MeCP2 in primary mouse hippocampal neurons results in reduction or enhancement of synaptic response respectively, primarily due to the number of glutamatergic synapses formed ([@bib14]). Furthermore, restoring MeCP2 levels rescued neurological defects associated with loss of MeCP2 the extent of which depends on timing of activation and dynamic variation in MeCP2 levels ([@bib24]; [@bib26]). Besides MeCP2, manipulation of target genes regulated by MeCP2 by genetic means or by indirect and nonspecific mechanisms has resulted in alleviating various features of RTT ([@bib22]; [@bib30]; [@bib37]; [@bib38]; [@bib49]; [@bib59]; [@bib61]).

Functional interaction between MeCP2 and brain-derived neurotrophic factor (BDNF) has been reported in various studies and MeCP2 has been known to regulate expression of BDNF ([@bib11]; [@bib12]; [@bib44]). *Bdnf* deletion from postnatal forebrain excitatory neurons of MeCP2 mutant mice resulted in an earlier onset of RTT while conditional BDNF overexpression delayed RTT onset and normalized spontaneous activity ([@bib12]). Similarly, endogenous MeCP2 knockdown reduced dendritic length in E18 hippocampal neurons, which was fully rescued upon BDNF overexpression ([@bib39]). Considering that BDNF is an important regulator of neurite outgrowth and synapse formation ([@bib16]; [@bib23]; [@bib25]; [@bib46]; [@bib51]; [@bib53]; [@bib60]; [@bib65]), it is essential to understand effects of BDNF modulation in *Mecp2^Null/y^* neurons specifically in steering neuronal growth and glutamatergic synapses. Early work has focused mainly on phenotypic rescue upon increasing BDNF levels in MeCP2-deficient mice but mechanistic interactions have not been resolved.

In this study, we examine putative causal mechanisms of BDNF impacting cellular growth as well as the formation of excitatory synapses in hippocampal neurons lacking MeCP2. We found that increased BDNF levels restored synaptic output and morphological phenotypes in MeCP2 deficient neurons in a cell autonomous and autocrine manner *in vitro* and *in vivo*. Importantly, blocking the BDNF pathway converted wildtype neurons to a phenotype that mimicked MeCP2-deficiency induced defects. These findings add to the current picture of BDNF signaling in stabilizing various features of RTT patients and are crucial for the profound understanding of BDNF-mediated therapeutic strategies and more generally, pathophysiology of the RTT disease.

Results {#s2}
=======

Loss, but not doubling of MeCP2, alters neurite outgrowth and neuronal soma size in hippocampal glutamatergic neurons {#s2-1}
---------------------------------------------------------------------------------------------------------------------

We previously reported that loss or doubling of MeCP2 results in altered glutamatergic synapse number in vitro and in vivo ([@bib14]) underlining tightly controlled MeCP2 dosage as a prerequisite for optimal synapse formation. Why MeCP2 levels are rate limiting in glutamatergic synapse formation is not clear, and could include pre- or postsynaptic factors that regulate synapse formation as well as factors that regulate general neuronal development. Hence, we began this analysis by examining the role of neurite outgrowth. Single-cell hippocampal autaptic cultures were utilized and particularly beneficial due to the unambiguous assignment of axon and dendrite and the ability to restrict analysis to a cell autonomous condition.

Axonal and dendritic outgrowths were measured during the first 12 days in vitro (DIV) from *Mecp2^Tg1^* and *Mecp2^Null/y^*neurons as well as control neurons derived from their respective WT littermates ([Figure 1](#fig1){ref-type="fig"}). Neurons were labeled with Tau1 and MAP2 to mark for axons and dendrites respectively ([Figure 1A](#fig1){ref-type="fig"}). Comparative analysis revealed that *Mecp2^Tg1^* neurons appeared normal and did not display any morphological deficits, with axonal and dendritic outgrowth similar to WT neurons ([Figure 1C and E](#fig1){ref-type="fig"}). However, *Mecp2^Null/y^* neurons showed a significant reduction of 23--41% and 27--41% in overall length of axons and dendrites respectively ([Figure 1B and D](#fig1){ref-type="fig"}). Considering these deficits in general growth and differentiation in *Mecp2^Null/y^* neurons, we analyzed the size of neuronal somata and observed a 24--33% reduction in soma size while *Mecp2^Tg1^* neuronal soma remained unchanged ([Figure 1F--H](#fig1){ref-type="fig"}). These results do not explain the Tg1 gain-of-function phenotype suggesting that an alternate mechanism may be necessary for enhanced synapse number. Additionally, the morphological findings reveal a general growth deficiency in glutamatergic neurons lacking MeCP2 possibly accounting for decreased synapse number.10.7554/eLife.19374.003Figure 1.Loss of MeCP2 alters neurite outgrowth and neuronal soma size.(**A**) Co-immunostaining of glutamatergic hippocampal neurons from WT and *Mecp2^Null/y^* mice at DIV 2, 4, 8 and 12 for Tau1 (cyan) and MAP2 (green). Scale bars represent 20 µm. (**B--E**) Mean axonal length and dendritic length measured at different time points for *Mecp2^Null/y ^*(**B,D**) and *Mecp2^Tg1^* neurons (**C,E**). (**F**) Somatic labeling of glutamatergic hippocampal neurons from WT and *Mecp2^Null/y^* mice at DIV 2, 4, 8 and 12 with MAP2. Scale bar represents 20 µm. (**G,H**) Mean soma area measured at different time points for *Mecp2^Null/y^* (**G**) and *Mecp2^Tg1^* neurons (**H**). Data shown as mean ± SEM. \*\*p\<0.01; \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.003](10.7554/eLife.19374.003)

BDNF overexpression in *Mecp2^Null/y^* autaptic neurons restores evoked EPSC magnitude, RRP size, synapse number, dendrite length, soma- and nucleus size {#s2-2}
---------------------------------------------------------------------------------------------------------------------------------------------------------

MeCP2 is a transcriptional regulator that activates or represses expression of several downstream genes based on cell type, origin, age and heterogeneity of brain region ([@bib11]; [@bib62]). Given that BDNF (i) is a consistent neuronal target gene of MeCP2 ([@bib11]; [@bib44]), (ii) is an essential regulator of synapse formation and dendritic complexity ([@bib23]; [@bib46]; [@bib60]), and that (iii) levels are reduced in MeCP2 knockout mice ([@bib12]); we investigated the mechanistic role of BDNF signaling in regulating synaptic output and synapse formation in *Mecp2^Null/y^* neurons at single-cell level.

To address this question, we utilized the lentiviral system driven by a synapsin promoter to overexpress BDNF in *Mecp2^Null/y^* and WT neurons to attempt rescue of growth deficits ([Figure 2A](#fig2){ref-type="fig"}). WT and *Mecp2^Null/y^* neurons expressing GFP were used as control. Indeed, BDNF overexpression in *Mecp2^Null/y^* neurons fully restored all morphological parameters analyzed. Particularly, glutamatergic synapse number, dendrite length and soma size in *Mecp2^Null/y^*neurons were reduced down to 51, 58 and 72% of WT and rescued up to 105, 89 and 102% of that of WT glutamatergic neurons respectively upon BDNF overexpression ([Figure 2B--E](#fig2){ref-type="fig"}). Similarly, nucleus size was reduced by 26% in *Mecp2^Null/y^*neurons and rescued up to 95% in BDNF overexpressing *Mecp2^Null/y^* neurons ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Overexpressing BDNF in WT neurons itself did not impact synapse number, dendrite length or soma size ([Figure 2L](#fig2){ref-type="fig"}). Further, lack of enhancement in synapse number upon BDNF overexpression in WT neurons verified that the *Mecp2^Tg1^* gain-of-function phenotype was not related to BDNF function and ascribed to potentially separate mechanism(s).10.7554/eLife.19374.004Figure 2.BDNF overexpression in *Mecp2^Null/y^* autaptic neurons normalizes cell morphology and restores synaptic output.(**A**) Experimental scheme of lentivirus-mediated BDNF overexpression in *Mecp2^Null/y^*neurons, showing neuronal membrane (black), BDNF (red) and TrkB receptor (blue). (**B**) Representative images of neuronal morphology under the following conditions (from left to right): WT, Null, Null + BDNF, Null + BDNF + ANA12, WT + ANA12. Dendritic outgrowth (top) and glutamatergic synapses (bottom) indicated by MAP2 (green) and VGLUT1 (red) labeling. Scale bars represent 20 µm. (**C--E**) Bar graphs show mean dendrite length (**C**), glutamatergic synapse number (**D**) and neuronal soma area (**E**). (**F**) Representative traces of evoked EPSCs recorded from autapses under the following conditions: WT, Null, Null + BDNF, Null + BDNF + ANA12, WT + ANA12, Null + ANA12. (**G**) Bar graph shows mean evoked EPSC amplitude. (**H**) Representative traces of average postsynaptic response to 5 s application of 500 mM sucrose. Experimental groups same as (**F**). (**J--K**) Bar graphs show mean RRP size (**I**), vesicular release probability P~vr~ (**J**) and paired-pulse ratio with 25 ms inter-stimulus interval (**K**). (**L**) Bar graph shows EPSC amplitude, RRP size and P~vr,~ PPR and dendrite length, glutamatergic synapse number and soma area, normalized to WT (dashed red line). Number of neurons (n) shown in the bars for all graphs. Data shown as mean ± SEM. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; ns: not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.004](10.7554/eLife.19374.004)10.7554/eLife.19374.005Figure 2---figure supplement 1.BDNF overexpression in *Mecp2^Null/y^* autaptic neurons normalizes nuclei size.Bar graph shows mean neuronal nuclei size. Number of neurons (n) shown in the bars for all graphs. Data shown as mean ± SEM. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; ns: not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.005](10.7554/eLife.19374.005)

We next examined functional implications of the observed morphological defects by measuring synaptic output in *Mecp2^Null/y^* neurons overexpressing BDNF. *Mecp2^Null/y^* neurons revealed 54% decrease in evoked EPSC amplitude (2.92 ± 0.42 nA, p\<0.05) and 58% decrease in RRP charge (0.37 ± 0.05 nC, p\<0.01) as compared to WT neurons (EPSC: 6.38 ± 0.9 nA; RRP: 0.89 ± 0.14 nC), both of which were rescued back up to 113 and 87% of WT levels, respectively (EPSC: 7.23 ± 0.97 nA, p\<0.01; RRP: 0.77 ± 0.09 nC, p\<0.01) ([Figure 2F--I](#fig2){ref-type="fig"}). We did not observe any differences in short-term plasticity or release efficiency in either WT or *Mecp2^Null/y^* neurons with or without BDNF overexpression, as reflected by the paired-pulse ratio (PPR) and vesicular release probability (P~vr~) measurements ([Figure 2J--L](#fig2){ref-type="fig"}). These findings further illustrate that interaction of MeCP2 and BDNF was predominantly related to scaling of neuronal size, growth and synaptic response.

Both TrkB inactivation and BDNF neutralization revert synaptic output and synapse number back to *Mecp2^Null/y^* levels {#s2-3}
-----------------------------------------------------------------------------------------------------------------------

Overall, synaptic and morphological deficits resulting from loss of MeCP2 function were fully re-established by restoring the ability of *Mecp2^Null/y^* neurons to synthesize increased levels of BDNF. We now asked if disruption of BDNF binding to TrkB could negate effects of BDNF overexpression in *Mecp2^Null/y^* neurons. The low molecular weight TrkB ligand, ANA-12, selectively binds to the TrkB receptor thereby blocking BDNF-induced TrkB activation and inhibiting intracellular signaling cascades downstream of TrkB ([@bib10]). Application of ANA-12 to the BDNF overexpressing *Mecp2^Null/y^* neurons reverted both synaptic output (evoked EPSC amplitude: 2.83 ± 0.47 nA, p\<0.001 and RRP size: 0.19 ± 0.02 nC, p\<0.001) ([Figure 2G and I](#fig2){ref-type="fig"}) and morphological phenotypes (synapse number: 151 ± 10, p\<0.01; dendrite length: 748 ± 46 µm, p\<0.05; soma size: 93 ± 4 µm^2^, p\<0.05 and nucleus size: 45 ± 2 µm^2^, p\<0.01) ([Figure 2C--E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) back to *Mecp2^Null/y^* control levels. Control groups included WT and *Mecp2^Null/y^* neurons both with and without application of ANA-12. Interestingly, *Mecp2^Null/y^* neurons treated with ANA-12 did not undergo any further loss-of-function effect and remained comparable to *Mecp2^Null/y^* control neurons ([Figure 2G and I](#fig2){ref-type="fig"}) indicating that the BDNF-TrkB canonical pathway was quantitatively disrupted in MeCP2-deficient neurons. On the other hand, WT neurons treated with ANA-12 displayed morphological as well as synaptic deficits and behaved similar to *Mecp2^Null/y^* neurons ([Figure 2G and I](#fig2){ref-type="fig"}). As before, PPR and P~vr~ remained unchanged in all conditions ([Figure 2J--L](#fig2){ref-type="fig"}). These results strongly suggest that BDNF synthesis and an active BDNF-TrkB pathway are essential for normal neuronal growth in WT as well as RTT-like hippocampal glutamatergic neurons.

Consistent with these results, we show that treatment of BDNF overexpressing *Mecp2^Null/y^* neurons with an anti-BDNF neutralizing antibody ([Figure 3A](#fig3){ref-type="fig"}) decreased EPSC amplitude and RRP size by 50 and 53% respectively ([Figure 3B--E](#fig3){ref-type="fig"}), thereby negating phenotype rescue seen via BDNF overexpression. Thus, we reveal that BDNF synthesis was clearly impaired in glutamatergic neurons lacking MeCP2. To further test the specificity of phenotype rescue, an alternate neurotrophic factor, nerve growth factor (NGF), was overexpressed in WT and *Mecp2^Null/y^* neurons ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). We found that NGF failed to restore normal synaptic transmission, emphasizing the specificity of the role of BDNF-TrkB in *Mecp2^Null/y^* neurons ([Figure 3---figure supplement 1B and C](#fig3s1){ref-type="fig"}). PPR and P~vr~ measurements remained unchanged across all conditions in both BDNF neutralization ([Figure 3F and G](#fig3){ref-type="fig"}) and NGF overexpression experiments ([Figure 3---figure supplement 1D and E](#fig3s1){ref-type="fig"}). These findings show that abolishing BDNF function as well as BDNF-induced TrkB activation affected synapse formation in *Mecp2^Null/y^* autaptic neurons, postulating the mechanistic role of BDNF in regulating synaptic function in RTT-like excitatory neurons.10.7554/eLife.19374.006Figure 3.BDNF neutralization fails to rescue physiological phenotypes while exogenous application of BDNF restores physiological and morphological phenotypes, reaffirming specificity of BDNF-TrkB interaction in *Mecp2^Null/y^* glutamatergic neurons.(**A**) Experimental scheme of lentivirus-mediated BDNF overexpression and BDNF neutralization in *Mecp2^Null/y^*neurons, showing neuronal membrane (black), BDNF (red), TrkB receptor (blue) and BDNF neutralizing antibody (cyan). (**B**) Representative traces of evoked EPSCs recorded from autapses under the following conditions: WT, Null, Null + BDNF, Null + BDNF + neutralization. (**C**) Bar graph shows mean evoked EPSC amplitude. (**D**) Representative traces of average current response to 5 s application of 500 mM sucrose. Experimental groups same as (**B**). (**E--G**) Bar graphs show mean RRP size (**E**), P~vr~ (**F**) and 25 ms ISI -- PPR (**G**). (**H**) Experimental scheme depicting exogenous application of BDNF in *Mecp2^Null/y^ *neurons, showing neuronal membrane (black), BDNF (red) and TrkB receptor (blue). (**I--M**) Bar graphs show mean evoked EPSC amplitude (**I**), RRP size (**J**), dendrite length (**K**), glutamatergic synapse number (**L**) and neuronal soma area (**M**). Number of neurons (n) shown in the bars for all graphs. Data shown as mean ± SEM. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; ns: not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.006](10.7554/eLife.19374.006)10.7554/eLife.19374.007Figure 3---figure supplement 1.NGF overexpression in *Mecp2^Null/y^* neurons does not rescue glutamatergic synaptic output.(**A**) Experimental scheme of lentivirus-mediated NGF overexpression in *Mecp2^Null/y^ *neurons, showing neuronal membrane (black), BDNF (red), TrkB receptor (blue), NGF (dark blue) and TrkA receptor (yellow). (**B--E**) Bar graphs show mean evoked EPSC amplitude (**B**), RRP size (**C**), P~vr~ (**D**) and 25 ms ISI -- PPR (**E**). Number of neurons (n) shown in the bars for all graphs. Data shown as mean ± SEM. \*p\<0.05; \*\*p\<0.01; ns: not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.007](10.7554/eLife.19374.007)10.7554/eLife.19374.008Figure 3---figure supplement 2.Exogenous application of BDNF does not alter release efficiency or short-term plasticity in *Mecp2^Null/y^* hippocampal neurons.(**A,B**) Bar graphs show mean P~vr~ (**A**) and 25 ms ISI -- PPR (**B**). Number of neurons (n) shown in the bars for all graphs. Data shown as mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.008](10.7554/eLife.19374.008)

Exogenous BDNF application in *Mecp2^Null/y^* neurons rescues physiological and morphological phenotypes {#s2-4}
--------------------------------------------------------------------------------------------------------

If BDNF synthesis were indeed disrupted and led to general growth and synaptic deficits in *Mecp2^Null/y^* neurons, exogenous application of BDNF should be able to bypass this deficiency and rescue loss-of-function. Neurons were treated with 50 ng/ml of recombinant human BDNF at DIV 2 and replenished every 2--3 days until DIV 14 when they were either taken for EPSC and RRP measurements or fixed for morphology analysis ([Figure 3H](#fig3){ref-type="fig"}).

Exogenous BDNF application normalized evoked EPSC amplitude ([Figure 3I](#fig3){ref-type="fig"}) and RRP size ([Figure 3J](#fig3){ref-type="fig"}) as well as re-established normal dendritic outgrowth ([Figure 3K](#fig3){ref-type="fig"}) and glutamatergic synapse number ([Figure 3L](#fig3){ref-type="fig"}) in *Mecp2^Null/y^* neurons. All restored phenotypes were specific to BDNF-TrkB since application of ANA-12 to *Mecp2^Null/y^* neurons treated with exogenous BDNF reverted evoked EPSC amplitude (44% decrease) and RRP size (66% decrease) as well as synapse number (39% decrease), dendrite length (47% decrease) and soma size (28% decrease) back to *Mecp2^Null/y^* levels ([Figure 3I--M](#fig3){ref-type="fig"}). No significant changes were seen either in PPR or P~vr~ measurements upon BDNF application ([Figure 3---figure supplement 2A and B](#fig3s2){ref-type="fig"}). These findings confirmed that *Mecp2^Null/y^* neurons were deficient in BDNF synthesis and revealed disrupted BDNF-TrkB signaling, which was bypassed upon exogenous application of BDNF.

BDNF overexpression restores synapse density in *Mecp2^Null/y^* glutamatergic neurons {#s2-5}
-------------------------------------------------------------------------------------

To verify if determining glutamatergic synapse number by estimating presynaptic VGLUT1+ puncta was correlated to identifying both pre- and postsynaptic colocalized puncta, we labeled WT and *Mecp2^Null/y^* neurons with Homer1, VGLUT1 and MAP2 under different experimental conditions ([Figure 4A](#fig4){ref-type="fig"}). First, we evaluated the density of VGLUT1 and Homer1 synaptic markers and found that MeCP2-deficient neurons displayed significant reduction in density of both markers, which were rescued upon BDNF overexpression and exogenous BDNF application ([Figure 4B and C](#fig4){ref-type="fig"}). We also observed that VGLUT1 and Homer1 densities were reverted back to *Mecp2^Null/y^* levels upon BDNF neutralization ([Figure 4B and C](#fig4){ref-type="fig"}). Next, we assessed the density of functional synapses by estimating the density of VGLUT1-Homer1 colocalized synaptic puncta. We found 41% decrease in VGLUT1-Homer1 puncta density in *Mecp2^Null/y^* neurons, which was restored up to 93 and 87% upon BDNF overexpression and exogenous BDNF application, respectively ([Figure 4D](#fig4){ref-type="fig"}). Additionally, the rate of colocalization of VGLUT1 with Homer1 was significantly reduced upon loss of MeCP2 (20% decrease) and restored up to 99 and 95% specifically via BDNF overexpression and exogenous BDNF, respectively ([Figure 4E](#fig4){ref-type="fig"}). Finally, we also examined the expression levels of VGLUT1 and Homer1 and found that intensities of both markers remained unchanged across all experimental conditions ([Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}).10.7554/eLife.19374.009Figure 4.BDNF overexpression in *Mecp2^Null/y^* glutamatergic neurons restores synapse density.(**A**) Representative images of WT and *Mecp2^Null/y^ *neurons labeled with MAP2, VGLUT1 and Homer1 under the following conditions (from top to bottom): WT, Null, Null + BDNF. Scale bar represents 3 µm. (**B--E**) Bar graphs show mean normalized VGLUT1 synapse density (**B**), Homer1 synapse density (**C**), colocalized VGLUT1-Homer1 synapse density (**D**), and normalized fraction of VGLUT1 puncta colocalized to Homer1 (**E**). Number of neurons (n) shown in the bars for all graphs. Data shown as mean ± SEM. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.009](10.7554/eLife.19374.009)10.7554/eLife.19374.010Figure 4---figure supplement 1.BDNF overexpression in *Mecp2^Null/y^* glutamatergic neurons does not alter expression levels of synaptic markers.(**A--C**) Bar graphs show mean normalized VGLUT1 fluorescence intensities in autaptic (**A**) and continental WT and *Mecp2^Null/y^ *neurons (**B**), and Homer1 fluorescence intensities (**C**). Number of synaptic puncta (n) shown in the bars for all graphs. Data shown as mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.010](10.7554/eLife.19374.010)

BDNF-induced TrkB activation regulates glutamatergic synapse number in a cell autonomous and autocrine manner {#s2-6}
-------------------------------------------------------------------------------------------------------------

We have observed so far that the loss-of-function phenotype seen in *Mecp2^Null/y^* neurons is reminiscent of that of conditional BDNF knockout mice ([@bib12]), and that physiological and morphological deficits are normalized upon BDNF overexpression as well as exogenous application, at single-cell level. If BDNF deficiency is responsible for the synaptic and growth deficits in *Mecp2^Null/y^* glutamatergic neurons, does paracrine signaling play a role in ameliorating loss of synapse number and function? This is particularly relevant for RTT patients wherein neighboring WT neurons may be impaired in their ability to restore loss of synapse number in *Mecp2^Null/y^* neurons despite mosaic expression of WT and mutant MeCP2. In order to address this question, we designed an *in vitro* RTT model to examine putative paracrine BDNF activity. We co-cultured WT and *Mecp2^Null/y^* hippocampal neurons and labeled neurons and corresponding synapses. For this purpose, we pre-incubated neurons of either genotype with distinct lentiviral constructs expressing Synaptophysin-GFP tagged to nucleus-localized RFP (WT) and Synaptophysin-mKate tagged to nucleus-localized GFP (*Mecp2^Null/y^*) to identify origin of synapses ([Figure 5A](#fig5){ref-type="fig"}-left panel). Co-labeling for VGLUT1 puncta and MAP2 enabled identifying glutamatergic synapses and their dendritic localization respectively, and synapse density was analyzed by estimating the number of colocalized Syp+ VGLUT1+ puncta. ([Figure 5B](#fig5){ref-type="fig"}). We found that *Mecp2^Null/y^* neurons showed 34% decrease in number of glutamatergic synapses ([Figure 5B](#fig5){ref-type="fig"}-left panel and **C**), which was also consistent with the data from single cells ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) and *in vivo* ([@bib14]).10.7554/eLife.19374.011Figure 5.TrkB activation specifically in *Mecp2^Null/y^* neurons in an *in vitro* RTT model normalizes glutamatergic synapse number in a cell autonomous and autocrine manner.(**A**) Left panel: Neuronal pair depicting lentivirus-mediated labeling of nucleus (NLS) and synapses of WT (NLS: red, Synaptophysin: green) and *Mecp2^Null/y^ *neurons (NLS: green, Synaptophysin: red), co-stained for MAP2 to identify synapses localized on dendrites. Right panel: Experimental scheme of lentivirus-mediated BDNF overexpression in WT or *Mecp2^Null/y^ *neurons, showing neuronal membrane (black), BDNF (red) and TrkB receptor (blue). (**B**) Representative images of co-cultured WT and *Mecp2^Null/y^ *neurons labeled with MAP2 under the following conditions (from left to right): WT/Null; WT+BDNF/Null and WT/Null+BDNF. Bottom panel shows WT (green) and Null (red) Synaptophysin+ synapses localized on a single dendrite. Scale bars on top and middle panel represent 20 µm. Scale bar on bottom panel represents 3 µm. (**C,D**) Bar graphs show mean glutamatergic synapse density (**C**) and nucleus size (**D**) for all co-cultured groups. Number of neurons (n) shown in the bars for all graphs. Data shown as mean ± SEM. \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001; ns: not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.011](10.7554/eLife.19374.011)

We next examined the impact of BDNF overexpression in *Mecp2^Null/y^* neurons to probe their ability to restore synaptic deficit ([Figure 5A](#fig5){ref-type="fig"}-right panel). To achieve BDNF overexpression, we pre-incubated WT and *Mecp2^Null/y^* neurons with distinct lentiviral constructs, expressing both BDNF and Synaptophysin-GFP (WT) or Synaptophysin-mKate (*Mecp2^Null/y^*) tagged to nucleus-localized RFP or GFP respectively, via P2A and T2A self-cleaving peptides (Refer Materials and methods). Overexpressing BDNF specifically in WT neurons did not have an impact on number of WT synapses or those formed by proximate *Mecp2^Null/y^* control neurons with the latter still displaying a 35% decrease in synapse number ([Figure 5B](#fig5){ref-type="fig"}-middle panel and **C**). Only overexpression of BDNF specifically in *Mecp2^Null/y^* neurons when co-cultured with WT neurons enhanced number of *Mecp2^Null/y^* synapses up to 99% of WT levels ([Figure 5B](#fig5){ref-type="fig"}-right panel and **C**); reaffirming that increased BDNF levels specifically in RTT-like neurons enabled rescue of synaptic phenotype. We then asked if BDNF overexpression also impacted nuclei size in *Mecp2^Null/y^* neurons. *Mecp2^Null/y^* neuronal nuclei were 23% and 27% smaller in size when co-cultured with WT and BDNF overexpressing WT glutamatergic neurons, respectively ([Figure 5D](#fig5){ref-type="fig"}). However, BDNF overexpression specifically in *Mecp2^Null/y^* neurons restored nucleus size up to 96% of that of co-cultured WT neurons ([Figure 5D](#fig5){ref-type="fig"}). These findings led us to two major conclusions. (i) Decreased synapse number and nucleus size in *Mecp2^Null/y^* neurons *per se* indicate a cell autonomous role for MeCP2 in regulating normal growth in glutamatergic neurons ([@bib3]; [@bib4]; [@bib33]). (ii) Restoration of both glutamatergic synapse number and nucleus size upon BDNF overexpression specifically in *Mecp2^Null/y^* neurons is best explained by an autocrine and highly focal effect for BDNF in regulating glutamatergic synapse formation and neuronal size.

Application of a TrkB agonist restores glutamatergic synapse number in *Mecp2^Null/y^* neurons {#s2-7}
----------------------------------------------------------------------------------------------

Given that restoration of autocrine BDNF secretion in itself is sufficient for normal growth of *Mecp2^Null/y^* neurons and that neighboring WT neurons are unable to support TrkB signaling or normalize synapse number, it is still possible to exogenously activate TrkB receptors on *Mecp2^Null/y^* neurons and restore glutamatergic synapse number. To test this, we repeated the above experiment in the presence of a TrkB agonist 7,8-dihydroxyflavone (7,8-DHF) ([Figure 6A](#fig6){ref-type="fig"}) that binds to its extracellular domain and activates TrkB-mediated downstream signaling ([@bib28]). Intriguingly, application of 500 nM 7,8-DHF at DIV 6, 9 and 12 equalized synapse number in all experimental groups. *Mecp2^Null/y^* synapses were restored back up to 94% and 97% of WT numbers when co-cultured with either WT neurons or WT neurons overexpressing BDNF, respectively ([Figure 6B](#fig6){ref-type="fig"}). As found in the single-cell system, 7,8-DHF did not have an effect on WT neurons overexpressing BDNF. Similarly, *Mecp2^Null/y^* synapses already overexpressing BDNF remained unaltered indicating that sufficient TrkB stimulation was already prevalent in these neurons ([Figure 6B](#fig6){ref-type="fig"}). These data proved that 7,8-DHF was able to bypass BDNF synthesis deficit and exogenously trigger TrkB activation in *Mecp2^Null/y^* neurons and augment synapse formation in a cell autonomous manner.10.7554/eLife.19374.012Figure 6.Cell autonomous BDNF-TrkB signaling regulates glutamatergic synapse number by functioning as a presynaptic rate-limiting factor.(**A**) Experimental scheme of lentivirus-mediated BDNF overexpression and exogenous application of TrkB agonist in WT or *Mecp2^Null/y^ *neurons, showing neuronal membrane (black), BDNF (red), TrkB receptor (blue) and TrkB agonist (green). (**B**) Bar graph shows glutamatergic synapse density for all co-cultured groups upon application of TrkB agonist, 7,8-DHF. (**C**) Example two-neuron scheme illustrating pre- and postsynaptic neurons (WT or *Mecp2^Null/y^*) forming synapses onto itself or onto the partner neuron, in a mixed WT/Null co-culture system. (**D**) Bar graphs show glutamatergic synapse density measured from a postsynaptic WT (clear bars) and Null (filled bars) neuron for all experimental groups. Number of neurons (n) shown in the bars for all graphs. Data shown as mean ± SEM. \*\*\*p\<0.001; ns: not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.012](10.7554/eLife.19374.012)10.7554/eLife.19374.013Figure 6---figure supplement 1.WT and *Mecp2^Null/y^* hippocampal neurons reveal transient and persistent fusion events upon stimulation, show equivalent activity-dependent BDNF secretion and membrane-resident BDNF-SpH fraction.(**A**) Representative images of a WT hippocampal neuron expressing BDNF-superecliptic pHluorin perfused with standard extracellular solution, 60 mM KCl, 50 mM NH~4~Cl and washout with extracellular solution (left to right). Scale bar represents 10 µm. (**B**) BDNF fluorescence (ΔF/F~0~) over time reflecting fusion events upon application of KCl, MES and NH~4~Cl solutions. Black line indicates duration of KCl, MES and NH~4~Cl application. (**C**) Average of BDNF fluorescence (ΔF/F~0~) after NH~4~Cl application (WT, n = 1521 events, Null, n = 948 events). (**D**) Bar graph shows activity-dependent BDNF release of WT (1464 events) and *Mecp2^Null/y^ *neurons (895 events). (**E,F**) Representative traces of BDNF fluorescence (ΔF/F~0~) indicating transient and persistent fusion events upon KCl-induced membrane depolarization in WT (**E**) and *Mecp2^Null/y^ *neurons (**F**). (**G**) Bar graph shows BDNF-SpH fraction in WT and *Mecp2^Null/y^ *neurons indicating surface accumulation of BDNF upon acid wash (MES, pH 5.5; WT, 1480 events; *Mecp2^Null/y^*, 900 events). Data shown as mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.013](10.7554/eLife.19374.013)

These findings reveal a crucial mechanism wherein BDNF has an autocrine and cell autonomous role, potentially activating TrkB receptors only on the same neuron via a positive feed forward system, thereby regulating excitatory synapse formation and normal growth of *Mecp2^Null/y^* neurons.

BDNF controls glutamatergic synapse number acting as a presynaptic rate-limiting factor in a MeCP2-dependent manner {#s2-8}
-------------------------------------------------------------------------------------------------------------------

We then asked if loss of BDNF activity affects glutamatergic synapse formation through impairment of pre- or postsynaptic function. To address this question, we analyzed WT and *Mecp2^Null/y^* glutamatergic synapse densities, as described before, from proximal dendrites of identified WT and *Mecp2^Null/y^* postsynaptic neurons ([Figure 6C](#fig6){ref-type="fig"}). We reasoned that in case of a presynaptic mechanism, *Mecp2^Null/y^* glutamatergic synapse densities would remain unchanged whether formed onto a WT or *Mecp2^Null/y^* postsynaptic neuron. Indeed, we found that the densities of *Mecp2^Null/y^* glutamatergic synapses were similarly (56 and 45%) decreased when formed onto WT as well as *Mecp2^Null/y^* postsynaptic neurons, respectively ([Figure 6D](#fig6){ref-type="fig"}-left). By contrast, in case of presynaptic *Mecp2^Null/y^* neurons overexpressing BDNF, densities of Null glutamatergic synapses made onto WT and *Mecp2^Null/y^* postsynaptic neurons were restored up to 87 and 86% of WT levels ([Figure 6D](#fig6){ref-type="fig"}-right). This analysis strongly suggests that BDNF deficiency in cultured glutamatergic neurons reduces overall synaptic output without impairing the ability to receive glutamatergic synaptic input.

Neurons lacking MeCP2 have smaller somata and nuclei as compared to WT in hippocampal CA1 of *Mecp2^+/-^* mice {#s2-9}
--------------------------------------------------------------------------------------------------------------

The autocrine role of BDNF secretion in an *in vitro* RTT model might argue that in heterozygous mice with mosaic MeCP2 expression patterns mimicking RTT, impaired BDNF synthesis may contribute to a persistent growth deficit specifically in neurons lacking MeCP2 *in vivo*. In addition to smaller somata in *Mecp2^Null/y^* neurons, reduced neuronal nuclei size has been reported across previous MeCP2 loss-of-function studies ([@bib15]; [@bib55]) that has been shown to be rescued by administering 7,8-DHF to *Mecp2^Null/y^* mice ([@bib30]). Hence, we looked at the soma area and nucleus size of CA1 neurons in two- and eight-week old *Mecp2^+/-^* mice to examine if there is a persistent phenotype in MeCP2-deficient neurons. For this purpose, we labeled the hippocampal CA1 for MeCP2, MAP2 and DAPI to perform quantitative analysis of MeCP2-positive and --negative neuronal nuclei ([Figure 7A and B](#fig7){ref-type="fig"}). Strikingly, we found that MeCP2-negative neuronal somata were 20 and 14% smaller than that of MeCP2-positive neurons in two- ([Figure 7C](#fig7){ref-type="fig"}) and eight-week old ([Figure 7D](#fig7){ref-type="fig"}) *Mecp2^+/-^* mice respectively. Similarly, MeCP2-negative neuronal nuclei were 18 and 21% smaller than MeCP2-positive neurons in two- ([Figure 7E](#fig7){ref-type="fig"}) and eight-week old ([Figure 7F](#fig7){ref-type="fig"}) *Mecp2^+/-^* mice respectively. These *in vitro* and *in vivo* findings together validate a cell autonomous effect and autocrine role for BDNF secretion in *Mecp2^Null/y^* neurons and lead to promising avenue for future investigations studying cell autonomous effects of BDNF and MeCP2.10.7554/eLife.19374.014Figure 7.MeCP2-deficient hippocampal CA1 neurons have smaller somata and nuclei in *Mecp2^+/-^* heterozygous mice *in vivo*.(**A**) Representative images of hippocampal CA1 from *Mecp2^+/-^* mice labeled for DAPI (blue), MAP2 (green) and MeCP2 (red) at two- (top) and eight-weeks of age (bottom). Scale bar represents 50 µm. (**B**) Representative images of hippocampal CA1 from *Mecp2^+/-^* mice labeled for DAPI (blue) and MeCP2 (green) at two- (top) and eight-weeks of age (bottom). Scale bar represents 50 µm. (**C--F**) Scatter plots show mean soma area and nucleus size of MeCP2+ and MeCP2- neurons at two- (**C,E**) and eight-weeks of age (**D,F**). Number of neurons (n) shown in all graphs. Data shown as mean ± SEM. \*\*\*p\<0.001; \*\*\*\*p\<0.0001.**DOI:** [http://dx.doi.org/10.7554/eLife.19374.014](10.7554/eLife.19374.014)

Discussion {#s3}
==========

Previous MeCP2 loss-of-function studies have shown decrease in glutamatergic synapse number and synapse density as well as reduced dendritic complexity and arborization associated with loss of MeCP2 ([@bib3]; [@bib14]; [@bib29]; [@bib39]; [@bib68]) but underlying mechanisms are not fully understood. In our study, we find a generalized growth and differentiation defect in glutamatergic *Mecp2^Null/y^* neurons with MeCP2-deficient neurons displaying reduced neurite outgrowth and soma area ([Figure 1](#fig1){ref-type="fig"}). In examining causal mechanisms, we find a critical role for BDNF. The specific loss in neuronal growth can be attributed to suppression of BDNF synthesis since both synaptic output and morphological phenotypes could be restored by lentivirus-mediated and exogenous application of BDNF, in a TrkB-dependent manner ([Figure 2](#fig2){ref-type="fig"}). Moreover, we show that blocking BDNF-TrkB signaling in wildtype neurons leads to a MeCP2-deficient state, strongly arguing for nearly complete suppression of the canonical BDNF-TrkB pathway in mutant neurons. Further, we demonstrate that the BDNF-mediated growth pathway is strictly cell autonomous since (i) neighboring wildtype neurons fail to rescue *Mecp2^Null/y^* neuronal morphological deficits in a RTT model *in vitro* ([Figure 5](#fig5){ref-type="fig"}), and (ii) MeCP2-deficient neurons have smaller somata as well as nuclei in both two- and eight-week old *Mecp2^+/-^* mice *in vivo* ([Figure 7](#fig7){ref-type="fig"}), given the reduced BDNF protein levels in *Mecp2^+/-^* mice ([@bib64]) and reduced mRNA levels in postmortem brain samples from RTT patients ([@bib1]; [@bib21]). This cell autonomy further illustrates that a change in circuit activity is unlikely to explain synapse loss associated with MeCP2-negative neurons in RTT models.

Much attention has been received towards manipulating either MeCP2 levels or protein levels of MeCP2-regulated genes predominantly because reactivation of the *Mecp2* or target gene has been shown to rescue morphological phenotypes, behavior and overall neurological function ([@bib12]; [@bib14]; [@bib26]; [@bib34]; [@bib39]; [@bib47]; [@bib48]). The fact that several synaptic defects in *Mecp2^Null/y^* neurons might be fundamentally linked to simply BDNF synthesis despite MeCP2 regulating transcription of a myriad of target genes renders MeCP2-BDNF interaction extremely pivotal. Along these lines, endogenous MeCP2 knockdown reduced dendritic length in E18 hippocampal neurons, which was fully rescued upon BDNF overexpression ([@bib39]), which is in agreement with our rescue data ([Figure 2C](#fig2){ref-type="fig"}). Differential BDNF function based on brain region and neuronal subtypes has been emphasized across various studies. In particular, reduced BDNF levels in the brainstem of *Mecp2^Null^* mice increased the amplitude of spontaneous and evoked EPSCs in nTS (nucleus tractus solitarius) neurons, which were fully rescued upon exogenous BDNF application ([@bib34]). This is comparable to the BDNF-mediated rescue of synaptic function in glutamatergic *Mecp2^Null/y^* neurons in our study ([Figure 2F--I](#fig2){ref-type="fig"}).

That BDNF is a neurotrophin with poor blood-brain barrier penetration characteristics ([@bib52]) prompted the need for small molecule substitutes that act as TrkB agonists and activate TrkB signaling ([@bib28]; [@bib45]). Administration of TrkB agonists ([@bib30]; [@bib38]; [@bib59]) and other candidates including CX546 ([@bib49]), environmental enrichment ([@bib37]; [@bib42]), insulin-like growth factor-1 ([@bib61]), cysteamine ([@bib57]) and fingolimod ([@bib22]) to MeCP2 mutant mice ameliorated several behavioral and functional RTT phenotypes both *in vitro* and *in vivo*. In our unique WT/Null RTT-like model, 7,8-DHF application clearly substantiated the autocrine and cell autonomous function of BDNF as well as BDNF-TrkB feed-forward loop impairment in *Mecp2^Null/y^* neurons ([Figures 5C](#fig5){ref-type="fig"} and [6B](#fig6){ref-type="fig"}). Impaired BDNF-TrkB activity could be due to differential surface expression of postsynaptic TrkB receptors and therefore inadequate availability of surface TrkB for binding to BDNF. However, complete rescue of both physiological and morphological phenotypes upon BDNF overexpression ([Figure 2](#fig2){ref-type="fig"}) eliminated this possibility and highlighted a crucial upstream deficit in BDNF synthesis and release. Further studies are required to elucidate how 7,8-DHF functions to act *in vitro* and *in vivo* to ameliorate RTT symptoms and enable normalization of glutamatergic synapse numbers.

BDNF synthesis deficit in MeCP2 lacking neurons has resulted in different phenotypic effects across various studies. In particular, Wang and colleagues reported decrease in absolute amounts of BDNF released but also an increase in percentage of BDNF content available for spontaneous release in *Mecp2^Null/y^* nodose ganglion (NG) neurons ([@bib64]). This may argue for cell-type specific effects of BDNF. Alternatively in our study, we demonstrate that glutamatergic synaptic output is normalized in *Mecp2^Null/y^* hippocampal neurons upon restoring BDNF levels ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) and that BDNF neutralization experiments indicate a defect in synthesis ([Figure 3](#fig3){ref-type="fig"}), which suggest decreased availability of BDNF for release. By contrast, BDNF could also be functioning through other parallel pathways. For example, a study based on hippocampal slices demonstrated impaired activity-dependent endogenous BDNF release from presynaptic mossy fibers onto CA3 pyramidal neurons of symptomatic MeCP2 mutant mice that was correlated to impaired TRPC3 signaling ([@bib40]).

BDNF and other neurotrophins bind to the cell surface due to their highly positive charge at physiological pH ([@bib5]; [@bib8]; [@bib20]), and locally modulate developing synapses by spatially restricting BDNF action ([@bib67]). Additionally, several peptidergic hormones and secretory molecules including Wnt ([@bib9]; [@bib50]), Semaphorin 3A ([@bib6]; [@bib19]; [@bib58]) and BDNF ([@bib20]) have been shown to remain membrane resident after secretion. Indeed, we verified this hypothesis by examining the fate of BDNF secretion in WT and *Mecp2^Null/y^* hippocampal neurons using the BDNF-superecliptic pHluorin (BDNF-SpH) live-cell imaging assay ([@bib36]) ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) (Refer Materials and methods). We measured activity-dependent BDNF release by 60 mM KCl-induced depolarization, and quantified surface fraction of BDNF-SpH by application of pH 5.5 MES-buffered acid solution. We found that a significant fraction of BDNF-SpH remained membrane-resident as evident from MES-buffered acid quenching experiments ([Figure 6---figure supplement 1B and G](#fig6s1){ref-type="fig"}), without affecting activity-induced BDNF secretion in both WT and *Mecp2^Null/y^* neurons ([Figure 6---figure supplement 1D--F](#fig6s1){ref-type="fig"}). This complements our previous findings and shows that stable membrane deposits of BDNF could potentiate TrkB receptor activation cell autonomously and drive glutamatergic synapse number by confining activity to its own neurites. Additionally, the fact that activity-dependent regulated BDNF release was unaffected in MeCP2-deficient glutamatergic neurons suggested that the observed synaptic phenotypes were accounted for by a deficit in constitutive BDNF release. Further studies specifically measuring pre- and postsynaptic release of BDNF from WT and *Mecp2^Null/y^* cultured glutamatergic neurons are essential to determine the locus of activity-dependent regulation of excitatory synapses.

What is the functional purpose of this autocrine feed-forward signaling loop? There seems to be a link between intrinsic activity and growth in WT neurons by allowing BDNF to work on its own neurons, coupling neuronal firing patterns to their basic growth properties. This further implies that reduced activity in *Mecp2^Null/y^* neurons ([@bib12]; [@bib14]; [@bib18]; [@bib61]) may disrupt activity-dependent neuronal growth. This deficiency could be repaired by supplying an additional source of BDNF (or TrkB agonist) that activates WT-like TrkB signaling. BDNF has been suggested to act as an autocrine factor mainly in regulating dendrite development in adult-born granule cells (GCs) ([@bib65]) and promoting axon formation in embryonic hippocampal neurons ([@bib16]). In RTT pathophysiology in particular, we show for the first time that this localized autocrine function and cell autonomy of BDNF-TrkB together offer a plausible mechanism and explain why MeCP2 mosaicism in RTT females is ineffective in restoring phenotypes at a cellular, network or behavioral level. It may be possible that BDNF released could be less efficient in reaching neighboring neurons in co-cultures; however, the cell autonomous effect observed in autaptic neurons *in vitro*, and *in vivo*, as well as the autocrine BDNF dependence seen *in vitro*, argue against putative BDNF paracrine effects. However, what remains to be understood is if the predominant impact of impaired BDNF signaling on circuitry stems from the pre- or postsynaptic site. Initial morphological analysis showed axonal as well as dendritic growth deficiency ([Figure 1](#fig1){ref-type="fig"}). Further analysis in mixed co-culture experiments demonstrated a presynaptic deficit wherein densities of *Mecp2^Null/y^* glutamatergic synapses onto the postsynaptic neuron remained independent of genotype ([Figure 6D](#fig6){ref-type="fig"}). This points towards a major 'propagation' defect specifically in *Mecp2^Null/y^* neurons in a mosaic circuit wherein they receive synaptic input similar to WT neurons. However, MeCP2-deficient glutamatergic neurons show reduced capacity to communicate output signal to a postsynaptic neuron thereby reducing efficiency of innervation across specific brain regions and dampening synaptic output. In fact, one could postulate that glutamatergic neurons lacking MeCP2 are essentially not 'deaf' but 'mute'. Interestingly, there is evidence of non-cell autonomous mechanisms contributing to neuronal development ([@bib7]) and dendritic arborization of cortical pyramidal neurons ([@bib33]). In a mosaic brain, MeCP2-deficient mute neurons may contribute to reduced overall activity, which in turn could reduce activity-dependent BDNF secretion and thereby result in putative non-cell autonomous effects as well. Hence, future studies comparing wildtype and heterozygous *Mecp2^+/-^* mice may help reveal additional non-cell autonomous effects *in vivo*.

It will be important to determine how the proposed presynaptic BDNF-mediated mechanistic pathway relates to other cell types, as well as to investigate specific downstream signaling pathways that might be affected as a result of BDNF synthesis deficiency. For example, MeCP2-deficient GABAergic neurons show decrease in inhibitory quantal size with reduced Gad1 and Gad2 levels ([@bib13]) while BDNF released from postsynaptic target neurons acts locally to modulate GABAergic synapse formation ([@bib35]). More generally, besides providing a mechanistic role for BDNF in MeCP2 mutant neurons, our results substantiate the significance of manipulating BDNF-TrkB interaction as a potential therapeutic strategy in alleviating the course of the RTT syndrome.

Materials and methods {#s4}
=====================

Animals and cell culture {#s4-1}
------------------------

All procedures to maintain and use mice were approved by the Animal Welfare Committee of Charité Medical University and the Berlin State Government. *Mecp2^Null/y^* male mice on a C57BLJ6/N background and/or *Mecp2^Tg1^* male mice on a FVB/N background were used for morphological and electrophysiological studies.

Primary hippocampal neurons were prepared from P0-P2 newborn mice and cultured on astrocyte feeder layers. First, WT astrocytes derived from P0-P2 mouse cortices were plated on collagen/poly-D-lysine microislands made on agarose-coated coverslips using a custom-made rubber stamp. For autaptic neuron studies, *Mecp2^Null/y^* or *Mecp2^Tg1^* neurons were cultured along with their littermate controls, plated at a density of 3000 neurons per 35 mm well and grown in Neurobasal-A media containing B-27 supplement and Glutamax (Invitrogen, Germany). For experiments utilizing continental cultures, glial proliferation was arrested by adding the antimitotic agent 8 μM 5-fluoro-2-deoxyuridine and 20 μM uridine (FUDR) to the astrocyte media. For experiments involving co-culture of WT and *Mecp2^Null/y^ *neurons, cells of either genotype were incubated with lentiviral constructs of interest for 1.5 hr at 37°C on a rotating wheel. Cells were then centrifuged at 1500 rpm for 5 min twice to remove any viral debris after which WT and *Mecp2^Null/y^* neurons were plated at a density of 14,000 neurons each per 22 mm well. This procedure enables identification of synapses formed by either genotype under desired conditions. For all experiments, neurons were incubated at 37°C for 12--14 d before subjecting them to further analysis.

Lentiviral constructs {#s4-2}
---------------------

Mouse cDNA constructs of pre-proBDNF, NGF and BDNF-SpH rat cDNA (kindly provided by Prof. Matthijs Verhage, Center for Neurogenomics and Cognitive Research, Amsterdam, The Netherlands) were cloned into vectors under control of the neuron-specific synapsin promoter. For co-culture experiments, we used a synapsin promoter-driven lentiviral shuttle vector expressing BDNF, cloned N-terminally to a self-cleaving T2A peptide of an expression cassette, which harbors (i) a nuclear localization sequence-tagged green fluorescent protein (NLS-GFP) or red fluorescent protein (NLS-RFP), which was fused C-terminally via a self-cleaving P2A peptide ([@bib32]) to (ii) Synaptophysin-mKate or Synaptophysin-GFP respectively (NLS-GFP-P2A-SypmKate-T2A-BDNF or NLS-RFP-P2A-SypGFP-T2A-BDNF). Control lentiviral vectors included NLS-GFP-P2A-SypmKate and NLS-RFP-P2A-SypGFP.

Lentiviral vectors and production were based on previously published protocols ([@bib41]). The production was done by the Viral-Core-Facility of the Charité -- Universitaetsmedizin Berlin. Briefly, HEK293T cells were cotransfected with 10 µg of shuttle vector and helper plasmids (pCMVdR8.9 and pVSV-G - 5 µg each) with X-tremeGENE 9 DNA transfection reagent (Roche Diagnostic, Switzerland). Virus-containing cell culture supernatant was harvested 72 hr post transfection and purified by filtration to remove cellular debris. Filtrate aliquots were flash-frozen in liquid nitrogen and stored at −80°C. Viral titer for all rescue experiments was determined using WT hippocampal continental neuronal cultures. Autaptic and continental hippocampal neurons were infected with lentivirus expressing BDNF or NGF on DIV 2. In case of co-culture experiments, WT and *Mecp2^Null/y^* neurons were incubated with lentivirus expressing tagged-BDNF and plated as described above.

Drug treatment {#s4-3}
--------------

Recombinant human BDNF (Promega, Madison, WI) was exogenously applied to the autaptic neurons at DIV 2 and added every 2--3 days at 50 ng/ml. The TrkB receptor antagonist ANA-12 (Tocris, Germany) was applied to neurons through culture medium at DIV 6 and added every three days at 10 µM. The BDNF neutralizing antibody α-BDNF (Millipore, Germany) was applied to neurons through culture medium at DIV 6 and added every three days at a dilution of 1:100. Neurons were treated with the TrkB agonist 7,8-DHF (Sigma Aldrich, Saint Louis, MO) at DIV 6, 9 and 12 at a working concentration of 500 nM.

Electrophysiology {#s4-4}
-----------------

Whole-cell voltage-clamp recordings were obtained from autaptic neurons at DIV 12--17. Currents were recorded from neurons held at −70 mV with a Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA) under the control of Clampex 9.2 (Molecular Devices). Data were sampled at 10 kHz and low-pass Bessel filtered at 3 kHz. Series resistance was compensated at 70% and only cells with \<12 MΩ resistance were included. In general, an approximately equal number of cells were recorded from all groups on a given experimental day and data from at least two independent cultures were analyzed per experiment.

Neurons were placed in standard extracellular solution, 300 mOsm pH 7.4, containing 140 mM NaCl, 2.4 mM KCl, 10 mM HEPES, 10 mM glucose, 2 mM CaCl~2~ and 4 mM MgCl~2~. The patch pipette internal solution, 300 mOsm pH 7.4, contained 136 mM KCl, 17.8 mM HEPES, 1 mM EGTA, 0.6 mM MgCl~2~, 4 mM ATP-Mg, 0.3 mM GTP-Na, 12 mM phosphocreatine, and 50 U/ml phosphocreatine kinase. Hypertonic sucrose solution was prepared as 500 mM sucrose in standard extracellular solution ([@bib56]).

Excitatory postsynaptic currents (EPSCs) were evoked by briefly depolarizing neurons from −70 mV to 0 mV for 2 ms. Application of hypertonic sucrose solution for 5 s was facilitated using a fast-flow system triggering release of the readily releasable pool (RRP) characterized by a transient inward current. RRP charge was estimated by integrating the total area under the transient curve obtained. Vesicular release probability (P~vr~) was determined by calculating ratio of EPSC charge over RRP charge. Short-term plasticity was determined by evoking 2 EPSCs with an inter-stimulus interval of 25 ms to measure paired-pulse ratio (PPR). PPR was determined by calculating the ratio of EPSC amplitude of second over the first synaptic response.

Electrophysiological data were analyzed offline using Axograph X (Axograph Scientific, Berkeley, CA), Excel (Microsoft, Redmond, WA) and Prism (GraphPad, La Jolla, CA). Unless specified otherwise, statistical significance was determined using one-way ANOVA with Tukey *post hoc* test (for three or more groups with normal distribution) or Student's *t test* (for two groups with normal distribution). In case of data not normally distributed according to D'Agostino-Pearson test, statistical significance was determined using non-parametric Kruskal-Wallis test with Dunn's *post hoc* test (for three or more groups) or Mann-Whitney *U* test (for two groups).

Immunocytochemistry {#s4-5}
-------------------

At DIV 13--15, cells were fixed in 4% paraformaldehyde for 15 min after which they were washed thrice in 1x PBS. After permeabilizing and blocking with 5% normal donkey serum (NDS) in 0.1% PBS-Tween (PBST) for 1 hr, cells were subsequently incubated with antibodies of interest overnight at 4°C. After washing coverslips thrice with 0.1% PBST for 15 min each, primary antibodies were labeled with secondary Alexa-Fluor 405, 488, 555 or 647 (1:500; Jackson, West Groove, PA) antibodies for 1.5 hr at room temperature. Coverslips were then washed twice with 0.1% PBST and twice with 1x PBS for 15 min each after which they were mounted on glass slides with either Mowiol or ProLong Gold Antifade Reagent (Invitrogen). Labeling was done with (i) guinea pig anti-VGLUT1 (1:4000; Synaptic Systems, Germany), (ii) rabbit anti-VGLUT1 (1:4000; Synaptic Systems), (iii) chicken anti-microtubule-associated protein 2 (MAP2) (1:2000; Millipore), (iv) mouse anti-Tau1 (1:1000; Millipore) and (v) guinea pig anti-Homer1 (1:500; Synaptic Systems).

Quantification of neuronal morphology {#s4-6}
-------------------------------------

First, 16-bit images were acquired on an Olympus IX81 inverted fluorescence microscope at 20x optical magnification with a CCD camera (Princeton MicroMax; Roper Scientific, Trenton, NJ). All images were analyzed using ImageJ software with relevant custom plugins. At least two independent cultures were imaged and analyzed for every experiment. All images were subject to uniform background subtraction and optimal threshold adjustment.

Quantification of VGLUT1+ puncta in autaptic WT or *Mecp2^Null/y^* neurons was used as a measure of presynaptic differentiation and estimating glutamatergic synapse number. This was done by identifying and counting all VGLUT1+ fluorescent spots localized on dendritic branches of every neuron using a custom macro in ImageJ. Quantification of all MAP2-positive processes with NeuronJ plugin was used to determine total dendrite length while measuring cross-sectional area across the MAP2+ cell body enabled estimation of area of neuronal somata. Nucleus cross-sectional area was measured by tracing the outline of the nucleus using NLS+ identified neurons. Total axonal length analysis was done by quantification of all Tau1+ MAP2- processes per neuron using NeuronJ plugin since an overlap of Tau1 labeling was observed in proximal MAP2-positive dendritic branches in several neurons. Pre- and postsynaptic puncta were estimated by manually counting individual VGLUT1+ and Homer1+ as well as double positive synapses on selected dendritic regions of interest. Glutamatergic synapse density in co-cultures was analyzed by manually counting VGLUT1 and synaptophysin double positive synapses on selected dendritic regions of interest.

Unless specified otherwise, statistical significance was determined using one-way ANOVA with Tukey *post hoc* test (for three or more groups with normal distribution) or Student's *t test* (for two groups with normal distribution). In case of data not normally distributed according to D'Agostino-Pearson test, statistical significance was determined using non-parametric Kruskal-Wallis test with Dunn's *post hoc* test (for three or more groups) or Mann-Whitney *U* test (for two groups).

Immunohistochemistry {#s4-7}
--------------------

Two animals per time point were fixed by transcardial perfusion with phosphate buffered-4% paraformaldehyde. Sectioning was done on a Leica cryostat CM3050 S and 25 µm coronal sections were obtained for both two- and eight-week old *Mecp2^+/-^* heterozygous mice. Sections were permeabilized with 1% Triton X-100 for 30 min and blocked with 5% NDS, 2% glycine, 0.5% Triton X-100 in PBS for 30 min at room temperature after which they were incubated in mouse anti-MeCP2 (1:500; Sigma) and chicken anti-MAP2 (1:2000; Millipore) overnight at 4°C. The sections were washed thrice with 1x PBS for 15 min each and stained with secondary Alexa 488 (1:500; Jackson) for 1 hr at RT. Sections were again washed thrice with 1x PBS for 15 min each and mounted on glass slides in ProLong Gold Antifade reagent with DAPI (Invitrogen).

Quantification of neuronal somata and nuclei in hippocampal CA1 {#s4-8}
---------------------------------------------------------------

Images were acquired on a Leica SP8 laser-scanning confocal microscope. Images were acquired as 8-bit images with 63x oil objective at 1024 × 1024 pixel resolution. Three to four sections were imaged per mouse per time point, images were acquired as z-stack with 15--20 optical sections and maximum intensity projections were created using Fiji. Hippocampal CA1 MeCP2+ and MeCP2- neurons were identified based on their nuclear punctate staining and outlines of corresponding neuronal DAPI+ nuclei were manually traced and cross-sectional area measured using Fiji. Neuronal somata were measured by manually tracing MAP2+ cell bodies across different optical sections and cross-sectional area was measured using Fiji.

BDNF-superecliptic pHluorin live cell imaging {#s4-9}
---------------------------------------------

We utilized an assay to monitor BDNF exocytosis in hippocampal neurons using a construct expressing BDNF tagged with superecliptic pHluorin (BDNF-SpH) ([@bib20]). BDNF-SpH was expressed in primary hippocampal neurons and characterized using the pHluorin live-cell imaging assay. Neurons were placed in standard extracellular solution as described in case of electrophysiological measurements and 256 × 256 pixel images were acquired on an Olympus IX71 inverted microscope equipped with an Andor iXon back-illuminated CCD camera and Polychrome V Illumination Unit (Till Photonics, Germany) at 60x magnification (numerical aperture 1.2) and a sampling rate of 1 Hz.

Neurons were stimulated by application of 60 mM KCl (prepared in standard extracellular solution) for 30 s using the fast-flow system as mentioned above. 60 mM KCl-induced membrane depolarization of BDNF-SpH-expressing neurons resulted in an increase in fluorescence (ΔF) that resembled a punctate-pattern distribution representative of BDNF exocytosis. Some fusion events decayed abruptly while many others decayed slowly or remained persistent. 50 mM NH~4~Cl solution was applied for 30 s to neutralize intracellular pH, causing an abrupt increase in fluorescence intensity enabling visualization of all BDNF-SpH containing compartments. Low pH (pH 5.5) solution of 2-(*N*-morpholino) ethanesulfonic acid was applied for 30 s for acid wash experiments, causing acute dimming of all surface resident BDNF-SpH proteins.

BDNF-superecliptic pHluorin image analysis {#s4-10}
------------------------------------------

BDNF release events were analyzed from stacks acquired from time-lapse recordings of BDNF-SpH containing vesicle clusters upon application of KCl, NH~4~Cl, pH 5.5 solutions or standard extracellular solution. BDNF release was analyzed from both synaptic and extrasynaptic sites. Background subtraction was done using Rolling Ball (50 pixel radius, ImageJ) for all image stacks and ROIs were marked to measure ΔF, using ImageJ. 4 × 4 pixel regions of interest (ROIs) were identified and peak change in fluorescence (ΔF) in response to KCl-induced stimulation normalized to initial fluorescence (F~0~ = average of five frames immediately before onset of stimulus) was measured as a function of time and averaged in Axograph X (Axograph). Baseline subtraction was done for each ROI per cell in Axograph X, and ΔF and ΔF/F~0~ values for all groups were analyzed in Prism (GraphPad). Release events were characterized by their abrupt increase in fluorescence upon application of KCl followed by a rapid or gradual decrease of fluorescence back to baseline levels, and normalized to their corresponding peak NH~4~Cl events. The same ROIs were probed in recordings upon application of NH~4~Cl or MES-buffered acid solutions. Acid quenched BDNF fraction was normalized to corresponding peak NH~4~Cl response, reflecting the non-internalized pool of BDNF vesicles that are either found on the neuronal surface or easily accessible from the extracellular space around the cell membrane.

Statistics {#s4-11}
----------

All statistical analyses were done using Excel (Microsoft) and Prism (Graphpad). Sample size estimation was done as described previously ([@bib14], [@bib13]). Detailed statistical data are reported in [Supplementary file 1.](#SD1-data){ref-type="supplementary-material"}
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Loss of MeCP2 disrupts cell autonomous and autocrine BDNF signaling in glutamatergic neurons\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, Sacha B Nelson (Reviewer \#1), is a member of our Board of Reviewing Editors and the evaluation has been overseen by a Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

It is *eLife* policy that titles should convey some details of the system under study. In this case it might be helpful to add the word \"mouse\" or \"mammalian\" to the title.

Summary:

Sampathkumar, Rosenmund, and colleagues use primary neuronal cultures, genetics, pharmacology and electrophysiology to investigate the role of BDNF signaling in mediating neuronal effects of mutations in MeCP2, the gene affected in Rett Syndrome. Although this is a well developed area of research, the authors provide a unique new set of insights showing that BDNF completely accounts for the observed cellular phenotypes and that the signaling is a local autocrine feed-forward mechanism that increases synapse number in a cell autonomous presynaptic fashion.

Essential revisions:

1\) Two of the reviewers were concerned about the lack of a direct connection to in vivo analyses. This could be addressed by:a) Altering the text to limit the conclusions to those about the cell autonomous biology of isolated glutamatergic neurons from a Rett model, omitting those about the disease per se;b) Shoring up the in vivo observations to better integrate them into the rest of the manuscript. Specifically, nuclear size should also be measured in the cultured neurons and whether or not this is cell autonomous and BDNF-dependent should be assessed, ideally by comparing WT, mutant and BDNF overexpressing neurons. It would also be helpful to assess whether or not there are additional non-cell autonomous effects in vivo by comparing heterozygote to wild type animals.

2\) Reviewers were also concerned about using two presynaptic markers rather than a pre- and postsynaptic marker to count synapses. At the very least, some of the observations should be repeated with an additional postsynaptic marker and the degree of correlation between pre-/post- identified synapses and pre-only synapses should be stated (for example Vglut and PSD95 would be good markers). In addition, it is important to rule out the possibility that synapse counts are influenced by the level of expression of the synaptic markers, as opposed to changes only in the physical presence or absence of synapses.

3\) Reviewers felt that a clearer and more detailed explanation was needed concerning the basis for the authors\' conclusion that there is no difference in BDNF release between WT and null cells, particularly given the NH~4~Cl data showing a lower fluorescence signal in the WT cells. In addition, it was felt that the authors need to clearly articulate a plausible hypothesis as to why autocrine, but not paracrine BDNF signaling would rescue the phenotypes they measured. It was suggested that characterizing TrkB phosphorylation under the conditions of bath application, and BDNF overexpression may help reveal the difference between autocrine and paracrine effects.

4\) Reviewers were concerned that there was not sufficient evidence that BDNF overexpression was adequately achieved, especially in the mixed culture conditions. Also in the mixed cultures, how were contributions to synaptic measurements from excitatory synapses on interneurons excluded?

5\) Was the person performing the analyses blind to the genotype/treatment of neurons?

10.7554/eLife.19374.017

Author response

*\[...\] Essential revisions:*

*1) Two of the reviewers were concerned about the lack of a direct connection to* in vivo *analyses. This could be addressed by:a) Altering the text to limit the conclusions to those about the cell autonomous biology of isolated glutamatergic neurons from a Rett model, omitting those about the disease per se;b) Shoring up the* in vivo *observations to better integrate them into the rest of the manuscript. Specifically, nuclear size should also be measured in the cultured neurons and whether or not this is cell autonomous and BDNF-dependent should be assessed, ideally by comparing WT, mutant and BDNF overexpressing neurons. It would also be helpful to assess whether or not there are additional non-cell autonomous effects* in vivo *by comparing heterozygote to wild type animals.*

As requested by the reviewers, we have addressed 1(b) by including the following data:

We have measured nucleus size in culture from both autaptic neurons ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) as well as co-cultured neurons ([Figure 5D](#fig5){ref-type="fig"}). Please also see Results subsection "BDNF overexpression in *Mecp2^Null/y^* autaptic neurons restores evoked EPSC magnitude, RRP size, synapse number, dendrite length, soma and nucleus size" (for autaptic data) and "BDNF-induced TrkB activation regulates glutamatergic synapse number in a cell-autonomous and autocrine manner" (for co-culture data). In autaptic cultures, we found that nucleus size is smaller in *Mecp2^Null/y^* glutamatergic neurons and restored to WT levels by BDNF overexpression in a TrkB-dependent manner. In co-cultured neurons, we found that nucleus size remains reduced in *Mecp2^Null/y^* glutamatergic neurons although they are co-cultured with WT neurons. Furthermore, BDNF overexpression specifically in *Mecp2^Null/y^* neurons restored nucleus size up to WT levels. These findings demonstrate that change in nucleus size upon loss of MeCP2 is cell autonomous as well as BDNF-dependent in vitro. The analyses were done blind to genotype and treatment of neurons.

To further shore up the in vivo observations, we have additionally analyzed soma area of MeCP2+ and MeCP2- neurons in the hippocampal CA1 region of *Mecp2*^+/-^ mice ([Figure 7A, C and D](#fig7){ref-type="fig"}). Please also see Results subsection "Neurons lacking MeCP2 have smaller somata and nuclei as compared to WT in Hippocampal CA1 of *Mecp2^+/-^* mice" and Materials and methods subsection "Quantification of neuronal somata and nuclei in hippocampal CA1". We found that the soma of neurons lacking MeCP2 were 20% and 14% smaller than those of MeCP2+ neurons in 2- and 8-week old *Mecp2*^+/-^ mice, respectively. This phenotype is similar to that of nucleus size data in vivo. These data suggest that both soma area and nucleus size were reduced upon loss of MeCP2 in a cell autonomous manner in vitro and in vivo. Since both in vitro and in vivo data on nucleus and soma show significant reduction in MeCP2-deficient neurons in a mosaic condition, it is safe to conclude that cell autonomy (both in vitro and in vivo data) and BDNF dependence (from in vitro data) play a critical role in regulating neuronal growth and glutamatergic synapse formation. Because of the short time frame for revisions, we were only able to analyze soma area of MeCP2+ and MeCP2- neurons in *Mecp2*^+/-^ heterozygous mice and uncovered further cell autonomous effects. Nevertheless, we have discussed the role of putative non-cell autonomous effects in the sixth paragraph of the Discussion section.

*2) Reviewers were also concerned about using two presynaptic markers rather than a pre- and postsynaptic marker to count synapses. At the very least, some of the observations should be repeated with an additional postsynaptic marker and the degree of correlation between pre-/post- identified synapses and pre-only synapses should be stated (for example Vglut and PSD95 would be good markers). In addition, it is important to rule out the possibility that synapse counts are influenced by the level of expression of the synaptic markers, as opposed to changes only in the physical presence or absence of synapses.*

The reviewers raise an important point here: Are pre-/post- identified synapses and pre- only synapses correlated? This seems to be the case, as shown in the revised version of [Figure 4](#fig4){ref-type="fig"} with new experiments. Please also see Results subsection "BDNF overexpression restores synapse density in *Mecp2^Null/y^* glutamatergic neurons". We have labeled neurons with Homer1 as a postsynaptic marker, rather than PSD95 (for better specificity and signal to noise ratio in our hands), and VGLUT1 as a glutamatergic presynaptic marker; as seen in [Figure 4A](#fig4){ref-type="fig"}. We then evaluated synapse density of both VGLUT1+ ([Figure 4B](#fig4){ref-type="fig"}) and Homer1+ puncta ([Figure 4C](#fig4){ref-type="fig"}) as well as VGLUT1-Homer1 colocalized puncta ([Figure 4D](#fig4){ref-type="fig"}) and rate of colocalization of VGLUT1 to Homer1 ([Figure 4E](#fig4){ref-type="fig"}). We found that both VGLUT1 and Homer1 synaptic densities were reduced to a similar degree in MeCP2-deficient neurons and rescued to WT levels upon both BDNF overexpression and exogenous BDNF application. To check specificity, we treated WT and BDNF overexpressing *Mecp2^Null/y^* glutamatergic neurons with the anti-neutralizing BDNF antibody and found that restored pre- and postsynaptic densities were reverted to *Mecp2^Null/y^* levels. We also measured VGLUT1-Homer1 colocalized puncta as well as rate of colocalization of VGLUT1 to Homer1 and found decrease in colocalized puncta upon loss of MeCP2, rescued by BDNF overexpression and exogenous BDNF in a BDNF-dependent fashion. In congruence, Chao 2007 analyzed colocalized VGLUT-PSD95 synaptic puncta as well as rate of colocalization in *Mecp2^Null/y^* neurons, and observed reduced VGLUT1-PSD95 puncta and reduced rate of colocalization, similar to our findings. Altogether, these data indicate maturation defect in excitatory synapses upon loss of MeCP2.

The reviewers also raise questions regarding the expression levels of synaptic markers used. To address this, we have measured expression levels of VGLUT1 in both autaptic and continental neuronal cultures, and Homer1 expression levels (see [Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}). Please also see Results subsection "BDNF overexpression restores synapse density in *Mecp2^Null/y^* glutamatergic neurons". We do not observe any changes in synaptic marker expression levels and so can conclude that expression levels of pre- or postsynaptic markers do not influence synapse counts.

*3) Reviewers felt that a clearer and more detailed explanation was needed concerning the basis for the authors\' conclusion that there is no difference in BDNF release between WT and null cells, particularly given the NH~4~Cl data showing a lower fluorescence signal in the WT cells. In addition, it was felt that the authors need to clearly articulate a plausible hypothesis as to why autocrine, but not paracrine BDNF signaling would rescue the phenotypes they measured. It was suggested that characterizing TrkB phosphorylation under the conditions of bath application, and BDNF overexpression may help reveal the difference between autocrine and paracrine effects.*

We apologize for the lack of clarity in explaining the BDNF release data. BDNF release events were normalized to their corresponding peak NH~4~Cl events in WT and *Mecp2^Null/y^* neurons. This demonstrates that changes in NH~4~Cl data in WT and *Mecp2^Null/y^* neurons do not impact the quantification of BDNF release events. Hence, we can safely conclude that activity-dependent BDNF release remains unchanged upon loss of MeCP2. We have mentioned this in Materials and methods subsection "BDNF-superecliptic pHluorin live cell imaging" and in [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}.

Additionally, as asked by the reviewers, we have discussed in greater detail about autocrine versus paracrine BDNF signaling in the sixth paragraph of the Discussion section. While we agree with the reviewers that characterizing TrkB phosphorylation under different conditions is an interesting suggestion; we believe that autocrine BDNF signaling is predominantly responsible for rescue of measured phenotypes for the following reasons: (i) Our comprehensive analysis of morphological and physiological phenotypes in autaptic *Mecp2^Null/y^* neurons demonstrates that all measured phenotypes were rescued upon BDNF overexpression and exogenous BDNF application, in a TrkB-dependent manner. (ii) Specific restoration of glutamatergic synapse number and nucleus size in BDNF overexpressing *Mecp2^Null/y^* neurons co-cultured with WT neurons shows that these phenotypes are regulated in a cell autonomous manner via autocrine BDNF signaling. Furthermore, both phenotypes failed to be rescued by simply co-culturing WT neurons with *Mecp2^Null/y^* neurons, arguing against putative paracrine effects.

*4) Reviewers were concerned that there was not sufficient evidence that BDNF overexpression was adequately achieved, especially in the mixed culture conditions. Also in the mixed cultures, how were contributions to synaptic measurements from excitatory synapses on interneurons excluded?*

The reviewers raise an important point if BDNF expression was adequately achieved. This indeed seems to be the case as seen in [Figure 2](#fig2){ref-type="fig"}, where BDNF overexpression in autaptic *Mecp2^Null/y^* neurons convincingly rescued both morphological and physiological phenotypes. Furthermore, this rescue mimicked exogenous BDNF application data, as seen in [Figure 3](#fig3){ref-type="fig"}, in a BDNF- and TrkB-dependent manner as shown by BDNF neutralization and TrkB antagonist experimental data ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Additionally, commercial BDNF antibodies did not work effectively in our hands. Other elegant approaches to test specificity in future studies besides BDNF overexpression, neutralization and TrkB antagonist experiments, may include characterizing BDNF knockdown and rescue with exogenous BDNF. In the case of mixed co-cultures, we have strong proof of sufficient BDNF expression based on glutamatergic synapse number and nucleus size rescue data ([Figure 5C and D](#fig5){ref-type="fig"}). These data also mimic the in vitro autaptic data ([Figure 2](#fig2){ref-type="fig"}) as well as in vivo soma and nucleus data ([Figure 7](#fig7){ref-type="fig"}). This co-culture data is particularly significant since we designed a unique in vitro experimental labeling technique to closely mimic Rett in vivo mosaicism, wherein we were able to locate synapse origin based on genotype. To our satisfaction, results matched autaptic and in vivo data, hence confirming robustness of the experimental design.

To address the second question (exclusion of excitatory synapses on to interneurons), we labeled all co-cultured WT and *Mecp2^Null/y^* neurons with VGLUT1, besides MAP2 and intrinsic Syp-mKate and Syp-GFP, to specifically mark excitatory synapses. We were not able to label additionally for the vesicular GABA transporter VGAT since all 4 channels were utilized for MAP2, VGLUT1, Syp-mKate and Syp-GFP. However, in all fields of view analyzed from three hippocampal cultures, we observed that the vast majority of Syp+ synapses were also VGLUT1+. Hence, we believe that excitatory synapses were primarily formed on to excitatory neurons, and contributions of synaptic measurements from excitatory synapses on to interneurons, would did not influence our findings.

*5) Was the person performing the analyses blind to the genotype/treatment of neurons?*

Yes, of three cultures analyzed, analyses for the first two cultures were done blind to both the genotype as well as treatment of neurons.
